John Clapham

John C Professor John Clapham

Chief Operating Officer
Medical School

University of Buckingham
Hunter Street
Buckingham
MK18 1EG, UK
Tel (office): 01280 820195
Fax: 01280 820135
Email: john.clapham@buckingham.ac.uk

Biography

Professor Clapham gained his degrees and PhD from Birkbeck College, University of London and has worked in the pharmaceutical industry for over 30 years.

He started his career as a scientist with Beecham Pharmaceuticals (now GSK) and, from 2001, with AstraZeneca, first in Sweden then the UK. At AstraZeneca John was Senior Director of Bioscience providing project support, resource and strategy to the cardiometabolic disease area.

John has extensive experience of project management, capability and technology development, line management and people development. He has held senior leadership roles in both operational and disease area strategy teams.

Research

  • Drug discovery in diabetes, obesity and cardiovascular disease.
  • Appetite.
  • Energy expenditure.

Supervision

  • Undergraduate industrial placement (sandwich) students
  • PhD students under the CASE system
  • Postdoctoral Fellows at University of Warwick and University of Madrid
  • External PhD examiner for University of Buckingham and University College London

Peer Reviewed Publications (last 5 years and selected)

Harte AL, Tripathi, G, Reddy, N, Fernandez da Silva N, Barber T, Clapham JC, Al-Daghri N, Alokail MS, Fowler AE, O’Hare PJ, Kumar S, McTernan, PG (2013). NFkB as a potent regulator of inflammation in human adipose tissue, influenced by depot, adiposity, T2DM status and TNFa. Obesity 21(11): 2322-2330 doi:10.1002/oby.20336

Clapham JC (2012). Central control of thermogenesis. Neuropharmacology. Special Issue 63(1):111-123 doi: 10.1016/j.neuropharm.2011.10.014

Zhang LN, Gamo Y, Sinclair R, Mitchell SE, Morgan, DG, Clapham JC, Speakman JR (2012). Effects of chronic oral rimonabant administration on energy budgets of diet-induced C57BL/6 mice. Obesity 20(5): 954-962 doi:10.1038/oby.2011.357

Zhang LN, Mitchell SE, Hambly C, Morgan DG, Clapham JC, Speakman JR (2012). Physiological and behavioral responses to intermittent starvation in C57BL/6J mice. Physiology and Behaviour 105(2): 376 -387 doi:10.1016/j.physbeh.2011.08.035

Zhang L-N, Morgan D, Clapham JC, Speakman JR (2011). Factors predicting non-genetic variability in body weight gain induced by a high fat diet (HFD) in inbred C57BL/6J mice. Obesity 20(6): 1179-88 doi:10.1038/oby.2011.151

Clapham JC, Arch JRS (2011). Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacology and Therapeutics 131 (13): 295-308 doi:10.1016/j.pharmthera.2011.04.004

Zhang L-N, Morgan D, Sinclair R, Selman C, Mitchell S, Clapham JC, Speakman JR (2011). Effects of chronic oral administration of a melanin-concentrating hormone receptor 1 (MCHR1) antagonist (GW803430) on energy budgets and glucose homeostasis in diet induced obese C57BL/6J mice. Diabetes 22(3): 681-690 doi:10.1002/oby.20418

Wennerberg M, Cheng L, Hjorth S, Clapham J, Balendran A, Vauquelin G (2011). Binding properties of antagonists to cannabinoid receptors in intact cells. Fundamentals & Clinical Pharmacology 25(2): 200-210 doi:10.1111/j.1472-8206.2010.00843.x

Wennerberg M, Balendran A, Clapham JC, Vauquelin G  (2010).  Unravelling the complex dissociation of [3H]-rimonabant from plated CB1 cannabinoid receptor expressing cells. Fundamentals & Clinical Pharmacology 24 (2):181-187 doi:10.1111/j.1472-8206.2009.00756.x

Kos K, Baker AR, Jernas M, Harte AL, Clapham JC, O’Hare JP, Carlsson L, Kumar S, McTernan PG (2009). DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 11(4): 285-292 doi:10.1111/j.1463-1326.2008.00909.x

Haggerty C, Hoggard N, Brown DS, Clapham JC, Speakman JR (2008). Intra-specific variation in resting metabolic rate in MF1 mice is not associated with membrane lipid desturation in the liver.  Mech Ageing Dev 129(3):129-137 doi:10.1016/j.mad.2007.11.001

Moore GBT, Pickavance LC, Briscoe CP, Clapham JC, Buckingham RE, Wilding JPH (2008). Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes Obes Metab 10(3): 251-263 doi:10.1111/j.1463-1326.2007.00697.x

Adams AC, Clapham JC, Wynick D, Speakman JR (2008). Feeding behaviours in galanin knockout mice supports a role of galanin in fat intake and preference. J Neuroendocrinol 20(2): 199-206 doi:10.1111/j.1365-2826.2007.01638.x

Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, Harper JA, Reobuck SJ, Morrison A, Pickering S, Clapham JC, Brand MD (2002). Superoxide activates mitochondrial uncoupling proteins. Nature 415: 96-99 doi:10.1038/415096a 

Clapham JC, Arch JRS, Chapman H, Haynes A, Lister C, Moore GBT, Piercy V, Carter SA, Lehner I, Smith SA, Beeley LJ, Godden RJ, Herrity N, Skehel M, Changani KK, Hockings PD, Reid DG, Squires SM, Hatcher J, Trail B, Latcham J, Rastan S, Harper AJ, Cadenas S, Buckingham JA, Brand MD, Abuin A (2000). Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406: 415 – 418 doi:10.1038/35019082

Cai XJ, Widdowson PS, Harrold J, Wilson S, Buckingham R, Arch JRS, Tadayyon M, Clapham JC, Wilding J, Williams G (1999). Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 48: 2132 – 2137 doi:10.2337/diabetes.48.11.2132

Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KWM, Mossakowska D, Murphy GJ, Roxbee-Cox L, Smith SA (1998). Identification of high-affinity binding sites for the insulin sensitiser rosiglitazone (BRL 49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharm Exp Ther 284 (4): 751 – 759.

Find Your Course

Subject:
Level:
  • Our Awards

    TEF Gold

  • Prospectus

    Prospectus 2018-19

    Need a prospectus? Order one here.